Phase 4 N=46 Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study
Polycystic Ovary Syndrome
Primary: Peripheral Insulin Sensitivity at Baseline and 6 Months. — 2.2; 2.1; 3.2; 2.0 mg/kg/min per uU/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=110 S. Aureus Screening and Decolonization
Wound Infection Due to Staphylococcus Aureus · MRSA Infection of Postoperative Wound
Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants
Phase 4 N=509 Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
Prostate Cancer
Primary: Progression Free Survival (PFS) — 5.7; 5.6 months — p=0.2176
Phase 4 N=54 A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine
HIV
Primary: Number of Participants With Sustained Virologic Response — 33 Participants
Phase 4 N=676 Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)
Atrial Fibrillation
Primary: Incidence of Major Bleeding Events (MBEs), as Defined by the International Society on Thrombosis and Haemostasis (ISTH) — 1.6; 6.9 percentage of participants — p=0.0009
Phase 4 N=65 Simplified Insulin Protocol Using Lantus in Elderly
Diabetes
Primary: Change in Duration of Hypoglycemia Episodes — 277; 111; 97 minutes of hypoglycemia
Phase 4 N=34 Glargine Versus NPH in Patients With Chronic Kidney Disease
Type 2 Diabetes Mellitus · Chronic Kidney Disease
Primary: Difference in A1c Levels — 8.86; 8.21; 7.95; 8.44 percentage — p=0.00045
Phase 4 N=254 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Overactive Bladder
Primary: Percentage of Participants Who Achieve a 100% Reduction in Urinary Incontinence Episodes — 32.0; 7.2 percentage of participants
Phase 4 N=41 Iloperidone in Mixed States of Bipolar Disorder
Bipolar Disorder
Primary: Measure of Response by Change From Baseline to End of Study in BISS Depression and Mania Scale Scores — 35.7; 61.8; 25; 48 percentage change in score on BISS scale…
Phase 4 N=11 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
Intermittent Explosive Disorder · Childhood Aggression · Oppositional Defiant Disorder
Primary: Number of Participants That Were Responders — 0; 5 Participants
Phase 4 N=60 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Number of Participants With Meningococcal Serogroups A, C, Y, and W-135 Antibody Titers >=1:128 — 43; 56; 56; 15 Participants
Phase 4 N=62 Enoxaparin Dosing in Obesity
Obesity
Primary: Proportion of Patients With an Initial Therapeutic Anti-Xa Level at Steady State in Each Group — 25; 20 Participants
Phase 4 N=6 Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
Parkinson's Disease · Deep Brain Stimulation Surgery
Primary: Change in Average Population Spiking Activity — 42.8 Percent change
Phase 4 N=52 Positive Expiratory Pressure for the Treatment of Acute Asthma in Children
Asthma
Primary: Change in Pulmonary Asthma Score (PAS) — 0.9; 0.4 mean PAS score
Phase 4 N=24 Vilazodone for Separation Anxiety Disorder
Separation Anxiety Disorder
Primary: Clinical Global Impression-Improvement Scale — 7; 4 Participants — p=.064